Finch Therapeutics Group, Inc. FNCHQ
Set alert
At close · Sep 30
- YTD
- +7.81%
- 1 year
- +7.81%
- Open
- 7.75
- Prev close
- 10.35
- Mkt cap
- 16.62M
- Vol
- 600
- Avg vol
- 1.10K
- EPS
- -6.92
- P/E
- -1.50
More statistics
- Low
- 7.00
- High
- 10.35
News
7 months ago defenseworld.net
Finch Therapeutics Group (NASDAQ:FNCH) Stock Price Down 2.7% – Here’s What Happened
Finch Therapeutics Group, Inc. (NASDAQ: FNCH - Get Free Report) dropped 2.7% during trading on Wednesday. The stock traded as low as $12.50 and last traded at $12.50. Approximately 283 shares traded…
9 months ago defenseworld.net
Contrasting Finch Therapeutics Group (NASDAQ:FNCH) and Eloxx Pharmaceuticals (NASDAQ:ELOX)
Profitability This table compares Finch Therapeutics Group and Eloxx Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Finch…
9 months ago defenseworld.net
Critical Contrast: Eloxx Pharmaceuticals (NASDAQ:ELOX) & Finch Therapeutics Group (NASDAQ:FNCH)
Risk and Volatility Eloxx Pharmaceuticals has a beta of -1720.35, suggesting that its share price is 172,135% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of…
10 months ago defenseworld.net
Financial Survey: ZIVO Bioscience (NASDAQ:ZIVO) versus Finch Therapeutics Group (NASDAQ:FNCH)
Earnings and Valuation This table compares Finch Therapeutics Group and ZIVO Bioscience"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per…
1 year ago seekingalpha.com
Arquitos Capital's Largest Holdings For Q1 2025
ENDI Corp's shares rose significantly, driven by a substantial increase in AUM and a value-unlocking transaction, suggesting further upside potential. Finch Therapeutics awaits a post-trial decision…
2 years ago globenewswire.com
Finch Announces Delisting from Nasdaq and SEC Deregistration
BOSTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Nasdaq: FNCH) (“Finch” or the “Company”), a microbiome technology company with a portfolio of intellectual property and…
3 years ago pennystocks.com
4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650%
Penny stocks to buy according to analysts. The post 4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650% appeared first on Penny Stocks to Buy, Picks, News and Information |…
3 years ago zacks.com
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates
Finch Therapeutics Group, Inc. (FNCH) delivered earnings and revenue surprises of -12.50% and 90.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead…
4 years ago zacks.com
Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why
Finch Therapeutics Group, Inc. (FNCH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near…
4 years ago globenewswire.com
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022
SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its…
4 years ago fool.com
Why Finch Therapeutics Stock Is Skyrocketing Today
The FDA, at long last, has lifted a clinical hold on Finch's C. diff program.
4 years ago investorplace.com
Why Is Finch Therapeutics (FNCH) Stock Up 30% Today?
Finch Therapeutics (FNCH) stock is rising higher on Friday following news that the FDA has released its clinical hold on CP101. The post Why Is Finch Therapeutics (FNCH) Stock Up 30% Today?
4 years ago pennystocks.com
Best Penny Stocks to Buy Today? 3 to Watch on April 29th
What you need to know about buying penny stocks on April 29th The post Best Penny Stocks to Buy Today? 3 to Watch on April 29th appeared first on Penny Stocks to Buy, Picks, News and Information |…
4 years ago benzinga.com
Finch Therapeutics' C. Difficile Infection Candidate Meets Primary Goal In Mid-Stage Study
Finch Therapeutics Group Inc (NASDAQ: FNCH) announced positive topline results from PRISM-EXT, an open-label extension of the PRISM3 Phase 2 trial evaluating CP101 to prevent recurrent C. difficile…
5 years ago globenewswire.com
Finch Therapeutics to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
SOMERVILLE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its…
5 years ago globenewswire.com
Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors
SOMERVILLE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its…
5 years ago globenewswire.com
Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SOMERVILLE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its…
5 years ago globenewswire.com
Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its…
5 years ago globenewswire.com
Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program
SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its…
5 years ago globenewswire.com
Finch Therapeutics Added to Russell 2000 and Russell 3000 Indexes
SOMERVILLE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its…